Fact.MR analysis finds demand for integrated design, production, validation, and release support is reshaping medical device outsourcing, with the market projected to expand at an 8.0% CAGR through 2036

Rockville, Maryland — September 16, 2026 — — The global medical device CDMO market is projected to increase from USD 90.0 billion in 2026 to USD 194.3 billion by 2036, registering an 8.0% CAGR over the forecast period, according to a new analysis by Fact.MR. The market was valued at approximately USD 83.3 billion in 2025.

The expansion reflects growing reliance on contract development and manufacturing partners that can support medical device companies across design, engineering, manufacturing, assembly, testing, packaging, validation, and regulatory documentation. As medical device manufacturers manage increasingly specialized products and capacity constraints, outsourcing is becoming a way to access qualified production capabilities without replicating every capability internally.

Get detailed market forecasts, competitive benchmarking, and pricing trends: https://www.factmr.com/connectus/sample?flag=S&rep_id=15810

Finished Device Outsourcing Creates New Demand for CDMO Partnerships

Finished medical devices are projected to account for 36.7% of the market by product type in 2026. The segment benefits from OEMs seeking qualified partners capable of taking responsibility for validated production and release-related documentation.

Cardiology is another major demand center, accounting for an estimated 28.9% share in 2026. Cardiac rhythm management and interventional cardiology programs often require controlled assembly, traceability, testing, and validation before production can be expanded.

Medical device OEMs are expected to represent 29.2% of demand by end user, reflecting their direct role in product specifications and supplier qualification. Meanwhile, direct OEM contracts are estimated to account for 30.0% of the distribution channel, supported by long qualification cycles and the need to establish responsibilities for quality and change control early in the relationship.

Design-to-Manufacturing Integration Becomes a Strategic Consideration

Product design and development is forecast to represent 36.2% of the service type segment in 2026. Early engineering decisions can affect tooling, manufacturability, validation requirements, and the timing of production transfer.

“For medical device CDMOs the test is simple. Buyers want proof that design work and manufacturing controls can move together without creating another review burden,” said Shambhu Nath Jha, Principal Consultant at Fact.MR.

The shift toward integrated services is particularly relevant for OEMs transferring products from development into commercial manufacturing. A CDMO capable of connecting engineering decisions with production controls can reduce the number of handoffs involved in moving a regulated device into routine supply.

Capacity Constraints and Qualification Requirements Shape the Market

Medical device companies continue to face the practical challenge of balancing internal engineering resources, cleanroom capacity, specialized tooling, and production requirements. Outsourcing can provide access to established manufacturing infrastructure while allowing OEMs to focus internal resources on product development and commercialization.

However, qualification remains a significant consideration. The Fact.MR assessment identifies validation workload, reimbursement pressure, supplier qualification time, and capacity or tooling constraints among factors that can limit the pace of outsourcing adoption. Buyers must establish that external manufacturing processes meet their quality requirements before shifting production at scale.

This creates opportunities for CDMOs that can combine manufacturing with validation documentation, testing, design transfer, assembly, and other lifecycle services. Specialty device programs and cardiology applications may offer additional opportunities as manufacturers seek external support for technically demanding products.

Regional Markets Show Different Growth Patterns

The United States is projected to record a 10.4% CAGR from 2026 to 2036, supported by substantial OEM demand and documentation-intensive procurement requirements. Germany is forecast to expand at 8.8%, while the United Kingdom is projected to grow at 8.0% during the same period.

Japan is estimated to register a 9.6% CAGR, while Canada is forecast at 7.2%. South Korea is projected at 6.4%, supported by technology-focused manufacturing and supplier qualification. Australia is expected to record a 5.6% CAGR.

These differences reflect varying regulatory environments, supplier ecosystems, manufacturing capabilities, and qualification requirements across countries.

Competitive Landscape

The medical device CDMO market includes established contract manufacturing and engineering providers with capabilities spanning device development, component manufacturing, assembly, and regulated production.

Companies profiled in the Fact.MR assessment include Jabil Inc., Integer Holdings Corporation, FLEX Ltd., Sanmina Corporation, Celestica Inc., Phillips-Medisize, and Plexus Corp. Their participation reflects the expanding role of external partners across medical device development and manufacturing programs.

Unlock 360° insights for strategic decision making and investment planning: https://www.factmr.com/report/medical-device-cdmo-market

Report Scope

The Fact.MR report analyzes the medical device CDMO market from 2026 to 2036 across product type, application, end user, distribution channel, service type, and region.

Product categories include finished medical devices, semi-finished products, raw materials, drug delivery devices, diagnostic devices, and surgical and therapeutic devices. Applications covered include cardiology, orthopedics, diagnostic imaging, in-vitro diagnostics, drug delivery, ophthalmology, and general and plastic surgery.

The study also evaluates Medical Device OEMs, pharmaceutical companies, hospitals and healthcare systems, biotechnology companies, diagnostic companies, and research institutions. Regional coverage includes North America, Latin America, Europe, East Asia, South Asia and Oceania, and the Middle East and Africa.

Explore More Related Studies Published by Fact.MR Research

Gaucher Disease Drugs Market- https://www.factmr.com/report/gaucher-disease-drugs-market

OTC Dry Eye Drops Market- https://www.factmr.com/report/otc-dry-eye-drops-market

Rat Mouse Model Market- https://www.factmr.com/report/rat-mouse-model-market

Vitamin D Therapy Market- https://www.factmr.com/report/vitamin-d-therapy-market

X-Ray Irradiation Market- https://www.factmr.com/report/x-ray-irradiation-market

About Fact.MR

Fact.MR is a market research and consulting firm providing industry intelligence across healthcare, food and nutrition, technology, chemicals, and other high-growth sectors. Its research combines secondary research, primary interviews, company analysis, market sizing, and forecasting to support strategic business decisions.

Media Contact

Fact.MR
Email: [email protected]
Website: https://www.factmr.com/